Zenas BioPharma's (ZBIO) Outperform Rating Reiterated at Wedbush

Key Points

• Wedbush reiterated its “outperform” rating on Zenas BioPharma and set a $45 price target, implying 54.11% upside from the prior close.
• Analyst sentiment remains broadly positive, with six Buy, two Hold and one Sell rating; MarketBeat reports a consensus “Moderate Buy” rating and average target of $44.29.
• Zenas reported a quarterly loss of $1.77 per share, missing the $1.12 consensus estimate, while revenue of $1 million fell well short of the $15 million forecast.

Zenas BioPharma (NASDAQ:ZBIO - Get Free Report)'s stock had its "outperform" rating reissued by investment analysts at Wedbush in a research note issued to investors on Friday,Benzinga reports. They currently have a $45.00 target price on the stock. Wedbush's price objective indicates a potential upside of 54.11% from the company's previous close.

Several other research analysts have also issued reports on the company. Zacks Research raised Zenas BioPharma from a "strong sell" rating to a "hold" rating in a research report on Friday, May 15th. Citigroup reissued a "buy" rating on shares of Zenas BioPharma in a research note on Wednesday, June 3rd. Morgan Stanley lifted their price objective on Zenas BioPharma from $21.00 to $22.00 and gave the stock an "equal weight" rating in a research note on Thursday, May 14th. Weiss Ratings downgraded shares of Zenas BioPharma from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Thursday, July 9th. Finally, HC Wainwright restated a "buy" rating on shares of Zenas BioPharma in a research report on Wednesday, June 3rd. Six analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $44.29.

Zenas BioPharma Stock Performance

Shares of ZBIO stock opened at $29.20 on Friday. The firm has a market capitalization of $1.84 billion, a price-to-earnings ratio of -3.45 and a beta of -1.03. The company has a current ratio of 11.94, a quick ratio of 11.94 and a debt-to-equity ratio of 1.04. The business's 50-day moving average price is $26.71 and its 200-day moving average price is $23.34. Zenas BioPharma has a 12 month low of $13.50 and a 12 month high of $44.60.

Zenas BioPharma (NASDAQ:ZBIO - Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The company reported ($1.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.12) by ($0.65). The firm had revenue of $1.00 million during the quarter, compared to the consensus estimate of $15.00 million. Equities research analysts forecast that Zenas BioPharma will post -4.47 EPS for the current year.

Insider Transactions at Zenas BioPharma

In related news, CEO Leon O. Moulder, Jr. purchased 60,000 shares of the firm's stock in a transaction on Monday, May 18th. The stock was purchased at an average cost of $16.88 per share, with a total value of $1,012,800.00. Following the completion of the purchase, the chief executive officer owned 96,928 shares in the company, valued at approximately $1,636,144.64. This trade represents a 162.48% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 22.00% of the stock is currently owned by corporate insiders.

Institutional Trading of Zenas BioPharma

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. SR One Capital Management LP boosted its holdings in Zenas BioPharma by 2.6% in the fourth quarter. SR One Capital Management LP now owns 5,037,854 shares of the company's stock worth $182,924,000 after acquiring an additional 126,315 shares in the last quarter. NEA Management Company LLC lifted its holdings in shares of Zenas BioPharma by 28.9% in the 4th quarter. NEA Management Company LLC now owns 3,523,219 shares of the company's stock worth $127,928,000 after purchasing an additional 789,500 shares in the last quarter. Federated Hermes Inc. grew its position in Zenas BioPharma by 45.9% in the 4th quarter. Federated Hermes Inc. now owns 2,715,578 shares of the company's stock valued at $98,603,000 after purchasing an additional 853,740 shares during the period. BlackRock Inc. bought a new stake in Zenas BioPharma during the 2nd quarter valued at $68,176,000. Finally, Vanguard Group Inc. raised its holdings in Zenas BioPharma by 25.0% during the fourth quarter. Vanguard Group Inc. now owns 1,453,065 shares of the company's stock worth $52,761,000 after buying an additional 290,307 shares during the last quarter.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company's proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source